Leerink Partners Starts Evommune Inc (EVMN) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Cantor Fitzgerald Starts Evommune Inc (EVMN) at Overweight
December 1, 2025 6:09 AM ESTCantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Evommune Inc (NYSE: EVMN) with a Overweight rating.
The analyst comments "We are very bullish on EVO756 for CSU given its differentiated mechanism, first-in-class potential, and positive data in CIndU, which meaningfully increases... More
Evercore ISI Starts Evommune Inc (EVMN) at Outperform
December 1, 2025 6:03 AM ESTEvercore ISI analyst Gavin Clark-Gartner initiates coverage on Evommune Inc (NYSE: EVMN) with a Outperform rating and a price target of $40.00.
The analyst comments "Evommune is an I&I (dermatology to start) focused company with a portfolio of assets. Lead indications are... More
William Blair Starts Evommune Inc (EVMN) at Outperform
December 1, 2025 5:06 AM ESTWilliam Blair analyst Matt Phipps initiates coverage on Evommune Inc (NYSE: EVMN) with a Outperform rating.
The analyst comments "We are initiating coverage of Evommune with an Outperform rating, based on the potential of the companys first-in-class MRGPRX2 inhibitor EVO756 in the... More
Morgan Stanley Starts Evommune Inc (EVMN) at Overweight
December 1, 2025 3:03 AM ESTMorgan Stanley analyst Judah Frommer initiates coverage on Evommune Inc (NYSE: EVMN) with a Overweight rating and a price target of $36.00.
The analyst comments: "Led by a management team with significant experience bringing anti-inflammatory therapies to patients (e.g., Ebglyss, Cimzia, Rezurock), Evommune is developing... More
